Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19

COVID-19 Clinical Trial

— PROVID-19  

Official title:

Evaluation of the Efficacy of Probiotics to Reduce the Duration and Symptoms of COVID-19 (PROVID-19 Study): a Randomized, Double-blind, Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04621071
• Other study ID #: 2021-3700
• Status: Completed
• Phase: N/A
• Start date: January 12, 2021
• Est. completion date: October 12, 2021

Study information

• Verified date: October 2021
• Source: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

COVID-19 disease caused by a new coronavirus (SARS-CoV-2) has received worldwide attention. No specific antiviral treatment is recommended for COVID-19 and no vaccine is currently available. Probiotics may be considered as an option of treatment since they have anti-viral effect, trigger immunomodulation and have low side-effects.

This randomized controlled trial aims to evaluate the efficacy of probiotics to reduce the duration and symptoms of COVID-19 in a symptomatic population tested positive to SARS-CoV-2, self-caring at home.

Description:

Rational: COVID-19 disease is caused by a new coronavirus (SARS-CoV-2) and has received worldwide attention. No specific antiviral treatment is recommended for COVID-19 and no vaccine is currently available so far. Several strong arguments support the study of probiotics for COVID-19: 1) probiotics act on viruses by various well described mechanisms (reduction of absorption, cellular internalization of the virus, production of metabolites / substances having a direct antiviral effect; and immunomodulation); 2) probiotics are considered with a high level of evidence (meta-analysis) to reduce diarrhea (associated with antibiotics and Clostridium difficile) and for respiratory tract infections; 3) probiotics are affordable and available with low side-effects.

Objectives:

1. Evaluate the effect of probiotics on the duration of COVID-19 in symptomatic patients, with moderate forms of the disease.

2. Evaluate the effect of probiotics on the severity of COVID-19 in symptomatic patients, with moderate forms of the disease.

3. Evaluate the effect of probiotics on the evolution of oral and fecal microbiota in symptomatic patients, with moderate forms of the COVID-19 disease.

Population: Men and women, 18 years or older, with a first positive test for COVID-19 in the last 5 days, having symptoms of the COVID-19, self-caring at home, living in Quebec for the next 60 days, able to take medication alone, with access to a phone or to the Internet.

Material: After providing consent remotely (electronic or recorded by phone), patients will receive by mail at home: : a leaflet explaining the study, the study product (probiotics or placebo) for 25 days, a container of maple syrup and a cup, a thermometer, an oximeter, a logbook, 2 saliva sample self-collection kits, 2 stool sample self-collection kits and instruction sheets.

Randomization: Patients will be randomized in one of the study groups (stratified by age and gender). The randomization is double-blind and uses a ratio 1:1. Group A: will take probiotics for up to 25 days / Group B: will take placebo for up to 25 days.

Follow-up: Upon inclusion in the study, the participant will complete a questionnaire that will focus on socio-demographic (age, marital status), medical (weight, height, general health, current medication, symptoms…), food intake and other relevant information. The participants will fill a daily booklet evaluating their symptoms, compliance to treatment, medication intake, temperature, oxygen saturation value, etc. For those who will be admitted to hospital, data on their admission, complications and treatments will be collected. At 55 days after their enrollment, will fill an end of study questionnaire (symptoms, satisfaction, well-being, etc.).

Samples: The study includes the optional collection of saliva and stool samples twice, on Day 1 (before the first product is taken) and on Day 10.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: October 12, 2021
• Est. primary completion date: August 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• First positive test for COVID-19 in the last 5 days;

• Having symptoms of the COVID-19 at enrollment;

• Self-caring at home;

• Living in Quebec for the next 60 days;

• Able to take medication alone;

• With access to a phone or to the Internet;

• Able to give informed consent.

Exclusion Criteria:

• Taking probiotic supplements at enrollment;

• Taking antibiotics for a reason other than COVID-19 at enrollment;

• Allergies to soy, lactose, yeast, maltodextrin, vitamin C, potato starch, magnesium stearate, hypromellose or titanium dioxide;

• Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio- corticosteroid therapy, immunosuppressive pathology);

• Was treated with chemo-radio-corticosteroid therapy in the last 6 months;

• Has active cancer;

• Taking immunosuppressive drugs (e.g. anti-rejection treatment after organ transplant);

• Already participating in another clinical trial;

• Is pregnant, expects to become pregnant in the next few months or is breastfeeding;

• Has any other condition that would prevent safe participation in the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Dietary Supplement:
• Probiotics (2 strains 10x10^9 UFC)
Probiotic vs Placebo (1:1)
• Placebo (potato starch and magnesium stearate)
Probiotic vs Placebo (1:1)

Locations

Country	Name	City	State
Canada	CIUSSS de L'Estrie-CHUS Hospital	Sherbrooke	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke	Lallemand Health Solutions

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of symptoms of the COVID-19	Number of days before symptoms disappear	During the period of the treatment (from Day 1 to Day 25)
Secondary	Severity of the COVID-19	Categorical distribution among: 1) at home without symptoms, 2) at home with symptoms, 3) hospitalized without O2 supplementation, 4) hospitalized with O2 supplementation, 5) admitted to intensive care unit, 6) deceased	During the period of the study, first day in (at randomization) to last day in (last follow-up 30 days after the end of treatment) (from Day 1 to Day 55)
Secondary	Evolution of oral and fecal microbiota	Metagenomic sequencing	At Day 1 (baseline) and Day 10 of the treatment